Showing posts with label Nephrology. Show all posts
Showing posts with label Nephrology. Show all posts

Sunday, May 1, 2011

Elevated pulse pressure and white coat effect

Can we differentiate white coat effect from true hypertension in the office?
Difficult(we usually need either a 24 hr ambulatory BP monitoring or frequent home BP measurements.....both of which are cumbersome, and cant be done regularly).....but may be possible.....says Dr.Ahn from Korea, when he presented his study in the American College of Cardiology Scientific sessions earlier this month. Lets see what they found out..


They took 1087 outpatients with chronically treated hypertension, and checked home BP twice daily for 2 week, and then checked it in the office. White coat effect was defined as a difference between the physician's BP and the home BP of above 20 mm Hg systolic or 10 mm Hg diastolic BP. White-coat hypertension was found in 31% of patients. Pulse pressure of 60 mm Hg and above positively correlated with WCE by multivariate analysis. So the author concluded that... if a patient has an elevated BP reading in the clinic along with elevated pulse pressure, we can consider WCE before recommending antihypertensive agents. 


Some other interesting associations from the study : 
1. White-coat hypertension was not associated with age or gender in the study, 
2. Those with a family history of premature coronary disease were more likely to display WCE.
3. Those with diabetes or organ damage including the heart, as well as smokers, were less likely to show WCE.


The positive relationship with family history might be the result from the effects of anxiety and emotional stress, and the negative relationship with diabetes or smoking means that the WCE was relatively benign in these patients. Also pts with diabetes and organ damage may not be able to mount a stress response due to autonomic imbalance, LV dysfuction etc.


Is this important? Well.... it is...as we all know that white coat hypertension is a predecessor for chronic hypertension, as based on the findings from Italy(Hypertension 2009) ...in which thy followed nearly 1400 pts with white coat or masked hypertension , and found that 40% of patients with white coat effect progressed to develop Hypertension over a period of 10 years. So..YES...WHITE COAT HYPERTENSION needs to be identified and monitored closely. We usually dont treat WCH due to risk of hypotension...but they need to be monitored closely for development of hypertension. 

Friday, April 15, 2011

Antihypertensives - a little pharmacology helps

I came across this article recently about some interesting facts about antihypertensive medications and their pharmacology, which I though will be useful for practising clinicians like us!
The article describes about all 4 major types of antihypertensives. But the one which stands out is the angiotension converting enzyme inhibitors----WHY?     due to their difference in pharcological actions compared  to others.Let me start with a question..
If Mr.X tolerates(no hypotension) 5mg of Lisinopril, can we increase the dose to 40mg straightaway?
Most of us would say "NO". But the author says yes....and the explanation is pretty simple, interesting and true!
Unlike the other antihypertensives(beta blockers,CCB,diuretics), ace-i do not have a linear dose-response relationship....meaning that their BP lowering effect is not proportional to the dose. In other words....the efficacy of ace-i is the same irrespective of their dosage. Again...to make it more simple...a dose of 5mg of Lisinopril will lower the BP to the same extent as 40mg of Lisinopril. So why give 40mg in place of 2.5 mg? Well...the dose correlates with the duration of action.the higher the dose...the longer the duration of action!(Brit J Pharm 1984!)
It looks like...we have the low doses of ace-i in the market mainly to be used in patients with heart failure (who might have a low BP due to their other meds) to see if they can tolerate any hypotension induced by addition of ace-i. Also, the common side effect of ace-i...COUGH ..is not dose related.So here again..the dose doesnt matter.

So the article concludes that..ace-i don't have a linear dose-response curve, and so their dose can be increased to the maximal dose without any major concerns for hypotension. But ...one aspect of ace-i that the article doesn't discuss...is hyperkalemia. Well..the risk of hyperkalemia with ace-i is dose related, and whether it would be a good idea to go for a maximal dose straightaway or to increase it gradually, in this aspect.So..bottom line-----beacuse of the risk of hyperkalemia..we may not be able to go to a maximal dose directly, and not because of risk of hypotension.
A quick word abt hyperkalemia with ace-i : the risk is quite low on its own. The risk is high in CKD(4 fold risk), hepatic disease(almost 5 fold risk), taking>15 tablets(5 to 9 fold risk), advanced age(twice likely)...
(Pharm W Sci 2009)

Finally..the above article was published in American J of Cardio vasc Drugs 2011. The graph(above) is a modified graph from the same study. 

Thursday, March 24, 2011

Calcium gluconate in a digitalised heart with hyperkalemia! OK...or..NOT OK???

Today's morning report was about a young guy who was admitted with rhabdomyolysis, renal failure and hyperkalemia(K- 12mEq/dl) with sine wave pattern on his EKG. All this was due to a electrocution injury.So ...going through the management of hyperkalemia, someone pitched in the problem of giving Calcium gluconate in patients on Digoxin. Well....we had a couple of explanations for the interaction.So lets review the problem with these two drugs together.
First.....the mechanism of action of Digoxin- Digoxin inhibits the Na+/K+-ATPase(exchanges 2 K for 3Na) in the cardiac myocyte by competing with potassium,and causes intracellular sodium concentration to increase. This then leads to an accumulation of intracellular calcium by blocking the Na+-Ca++ exchange system. In the heart, increased intracellular calcium causes more calcium to be released by the sarcoplasmic reticulum, thereby making more calcium available to bind to troponin-C, which increases contractility (inotropy).


Second.....the mechanism of action of Calcium gluconate- a litlte more cellular pathology! . Normally the cardiac myocyte has a resting membrane potential(RMP is -90mV) and a threshold potential at which it is excited(TP is-75mV).So a 15mV depolarisation is needed to excite the myocyte. In hyperkalemia, the RMP becomes less negative (-80mV) , but the TP remains at -75mV. This means that ..now..only a 5mV depolarisation is enough to excite the myocyte. This is the cause of hyperexcitability leading to arrhythmia.Calcium gluconate...by increasing Ca transport across the membrane reduces the TP from -75mV to around -65mV ...restoring the 15mV depolarisation needed to excite the myocyte. (the numbers in mV are just an example)  ...... Annals of Emer Med 2011


Sooo...in patients on Digoxin(which causes positive inotropy through calcium)...if more calcium is given....it can lead to more intracellular calcium in mycocyte leading to what has been described as cardiac tetany due to prolonged depolarisation. So ,does hyperkalemia make this process worse?? Well, probably not. ------Since K+ and digoxin compete for Na/KATPase, the binding depends on the concentration of the two. In hyperkalemic state...K+ binds preferentially than digoxin, on Na/K ATPase, and thus resulting in diminished digoxin action. (to better understand...think about hypokalemic states...where digoxin will bind preferentially to the receptor, and hence result in digoxin toxicity!--which is well known)
A slightly different scenario would be...when some one(with no K+ problems) takes too much digoxin...which will also result in digoxin binding preferentially than K+,  to Na/KATP ase resulting in Dig toxicity. In this setting....pt may go hyperkalemia..as more K+ ends up extracellularly (due to not binding with Na/K ATPase), and if this patient gets Ca gluconate..then again..it can causes arrhythmias.


Bottom line is...if Calcium is given(and pt made hypercalcemic) to any pt on Digoxin ..there is a increased possibility for cardiac arrhythmias(PG Med J 1999) ...irrespective of whether they have hyperkalemia or not. 
Whether these pathophysiologies!! are clinically relevant is not clear, as these interactions are based on few case reports only. Have a look at this animal study (J clin Tox 2004) and this retrospective study on pts ..over 18 years from a hospital in Arizona(J Emer Med 2011).Both of them show no clinically relevant interaction of Calcium administration even in Digoxin toxicity.     !!!!!!!

Wednesday, March 2, 2011

Some key aspects of Surviving sepsis

The key recommendations covering all aspects of sepsis treatment were outlined in the 2008 update on Surviving sepsis campaign. This is a tribute to my 2 month CU rotation which I completed this week.....


Early goal-directed resuscitation of the septic patient during the first 6 hrs after recognition (1C)
Blood cultures before antibiotic therapy (1C);
 Imaging studies performed promptly to confirm potential source of infection (1C); 
Administration of broad-spectrum antibiotic therapy within 1 hr of diagnosis of septic shock (1B) and severe sepsis without septic shock (1D);
 Reassessment of antibiotic therapy with microbiology and clinical data to narrow coverage, when appropriate (1C); a usual 7–10 days of antibiotic therapy guided by clinical response (1D);
 Source control with attention to the balance of risks and benefits of the chosen method (1C);
 Administration of either crystalloid or colloid fluid resuscitation (1B);
 Fluid challenge to restore mean circulating filling pressure (1C); reduction in rate of fluid administration with rising filing pressures and no improvement in tissue perfusion (1D); Vasopressor preference for norepinephrine or dopamine to maintain an initial target of mean arterial pressure ≥65 mm Hg (1C); dobutamine inotropic therapy when cardiac output remains low despite fluid resuscitation and combined inotropic/vasopressor therapy (1C);
 Stress-dose steroid therapy given only in septic shock after blood pressure is identified to be poorly responsive to fluid and vasopressor therapy (2C); 
Recombinant activated protein C in patients with severe sepsis and clinical assessment of high risk for death (2B except 2C for postoperative patients).
 In the absence of tissue hypoperfusion, coronary artery disease, or acute hemorrhage, target a hemoglobin of 7–9 g/dL (1B);
 A low tidal volume (1B) and limitation of inspiratory plateau pressure strategy (1C) for acute lung injury (ALI)/acute respiratory distress syndrome (ARDS); 
Application of at least a minimal amount of positive end-expiratory pressure in acute lung injury (1C); head of bed elevation in mechanically ventilated patients unless contraindicated (1B); avoiding routine use of pulmonary artery catheters in ALI/ARDS (1A);
 To decrease days of mechanical ventilation and ICU length of stay, a conservative fluid strategy for patients with established ALI/ARDS who are not in shock (1C);
 Protocols for weaning and sedation/analgesia (1B); using either intermittent bolus sedation or continuous infusion sedation with daily interruptions or lightening (1B); avoidance of neuromuscular blockers, if at all possible (1B);
Institution of glycemic control , targeting a blood glucose <150 mg/dL after initial stabilization (2C);
 Equivalency of continuous veno-veno hemofiltration or intermittent hemodialysis (2B); 
prophylaxis for deep vein thrombosis (1A); 
Use of stress ulcer prophylaxis to prevent upper gastrointestinal bleeding using H2 blockers (1A) or proton pump inhibitors (1B); and consideration of limitation of support where appropriate (1D).


Our hospital has a Sepsis alert system whereby anyone getting into ER with tachycardia and fever will be eligible for a STAT call to the ICU resident (which was unfortunately 'I' for the last 2 months!!). http://www.survivingsepsis.org/About_the_Campaign/Documents/Final%2008%20SSC%20Guidelines.pdf


Friday, January 28, 2011

Tuesday, January 18, 2011

angioedema risk with ace-inhibitors

We recently had an african american male presenting with swollen tongue, lips and a stridor. was intubated for airway compromise..given epinephrine im, benadryl, ranitidine, hydrocortisone. Was extubated the next day after resolution of edema. This gentleman was started on Lisinopril 2 weeks ago for hypertension. This is likely...to be Angioedema due to ace-i!!


The pathophysiologic mechanism of angioedema with regard to ACE inhibitor therapy is believed to relate to the kallikrein-kinin plasma effector system. Bradykinin, which is normally degraded by kininase II/ACE, accumulates in tissues pts on ace-i.  Plasma bradykinin has been shown to increase up to 12-fold during acute angioedema attacks in patients with hereditary or acquired forms of angioedema. A case control study from 1997 showed consistently decreased levels of carboxypeptidase N(kininase1) and C1 esterase inhibitor in pts with angioedema secondary to ace-i Vs pts without angioedema on ace-i.

Another interesting theory has been the association of low levels of dipeptidyl peptidase 4( known to catabolise bradykinin) in pts with ace-i associated angioedema. (Hypertension 2002). The reason this is interesting is because ..... the recent DPP-4 inhibitors(Sitagliptin, Saxagliptin) that we use for diabetes work by inhibiting DPP-4. So if the above theory is true..then we might see an increased risk of angioedema in patients on these medications along with ace-i(as most diabetics need ace-i). Lets wait and see!!!!


Several risk factors for development of angioedema with ace-i have been proposed.The most important predisposing risk factor, evidenced by case-control studies, appears to be ethnic differences.The risk of angioedema with ACE inhibitors is higher in blacks and appears not to be related to dose, specific ACE inhibitors, or concomitant medications...as shown in this nice case control study(Clin Pharm & Ther 1996). Other risk factors are a history of idiopathic angioedema, head and neck surgery, and seafood allergy. 


This study from 1988 ...which looked at 3 studies...each with 12,0000 patients.....showed that the incidence of angioedema is high in the first week of starting Enalapril...and then declined. But previous tolerance to an ACE inhibitor does not exclude the risk for angioedema when therapy is modified to a different ACE inhibitor. Finally...the oberall incidence of angioedema with ace-i is around 0.1 - 0.6% over a period of 6 months (a rough estimate based on studies like OCTAVE  (again showing a higher incidence among African americans than other races)

Tuesday, January 4, 2011

urinary calcium and renal stones

Calcium oxalate stones are the most common type of renal stone.(around 75%). 3 types of stones can be caused by calcium- calcium oxalate, CaCO3, or CaHPO4. 


Calcium oxalate crystals can form at any pH and have various microscopic morphologies. It is estimated that about half of the oxalate in urine comes from ascorbic acid (vitamin C), which is a precursor to oxalate. Calcium oxalate crystals are also associated with ethylene glycol ingestion, another oxalate precursor. Calcium carbonate (CaCO3), the main component of marine shells and egg shells, can be found as small granular crystals in alkaline urine. Calcium carbonate crystals are not common in urine but when present can be mistaken for bacteria. Calcium phosphate (CaHPO4 or Ca[H2PO4]2) crystals can have different morphologies depending on their state of hydration and can be present in the urine sediment of neutral or slightly alkaline or acidic urine.


Eventhough calcium is involved in majority of stones....its measurement in urine is of limited value in predicting/diagnosing renal stones.This is because of a lot of other factors involved in stone formation( citrate, oxalate, urine Ph etc). Risk assessment using ratios such as the calcium/magnesium ratio, the calcium/citrate ratio, and the (calcium * oxalate)/(magnesium * citrate) ratio have met with little success, and are regarded to play a supplementary role in evaluation of renal stones.( Ped Nephrol 2009)


But Urine calcium can be used in assessing patients with primary hyperparathyroidism. A study done comparing biochemical parameters and treatment outcomes in stone formers with hyperparathyroidism Vs those without systemic disease...found ..a greater amount of calcium excretion in urine of stone formers with hperparathyroidism than in stone formers without systemic disease.(Brit J of Urol 2009) .Thus high Calcium creatinine clearance rate(or calcium creatinine ratio > 0.20) can be helpful in patients with hyperparathyroidism in predicting/assessing risk for stone formation. Interestingly, parathyroidectomy did not reverse the hypercalciuria or hypophosphatemia in these patients.


Increased Urinary calcium - > 300mg/24 hours
Increased calcium creatinine ratio - > 0.2 
A quick word about diet in calcium stones---- is reducing calcium in diet doesnt help( again because of multiple factors involved in stone formation). But reducing oxalate consumption prevents crystal formation and reduces stone formation.Have a look at this article from NEJM 2002 (hope u all have access)

Tuesday, December 14, 2010

a little step towards cost effectiveness - renal US

A renal ultrasound is a very good study that gives a lot of useful information for a lot of kidney diseases. Especially...in Acute Kidney injury(AKI) , it may change the management. But ,how frequently does it change the management...and how frequently should we do it in the setting of AKI? Well.......it gets done routinely in hospitals for evaluation of AKI ..to "rule out" obstruction. 
Recently...nephrologists at Yale tried to stratify patients who might need a renal US for evaluation of cause of hospital acquired AKI. (Arch of Int Med Nov 2010)


To identify the clinical risk factors for hydronephrosis, a derivation sample of 100 patients with hydronephrosis diagnosed with ultrasonography and 100 randomly selected controls was used. The results were subsequently validated using 797 ultrasonography studies obtained over 16 months. authors were able to find 7 factors associated with risk of hydronephrosis : history of hydronephrosis; recurrent urinary tract infections; diagnosis consistent with obstruction; nonblack race; and absence of the following: exposure to nephrotoxic medications, congestive heart failure, or prerenal AKI. 1 point awarded to each risk factor (except previous h/o hydro...which was considered high risk by itself). Pts were categorised into low risk(<2 points), intermediate risk(3 points) and high risk(>3 points). The overall incidence of hydro was 10%, and hydro needing intervention was 3%. In the low risk group...223 patients had to be screened to find one case of hydro needing intervention.(thats a lot of patients!). The model had very good sensitivity & a negative predictive value of 99% for hydro needing intervention. 


So......what do we have here?? A good proportion of patients with hospital AKI( categorised as low risk by this model) who would not need a renal US as part of their work up for AKI. The authors also calculated a savings of around $42,000 (based on a 30% reduction in US requests...($200/US) with an average of 700 US procedures in 1 year)


With regards to Community acquired AKI, we dont have similar kind of data...and the one we have is from 1991(AJKD) where they found the incidence of obstruction as a cause of AKI in 17% of patients with AKI...and it was mostly due to prostatic hypertrophy. It may be reasonable to do routine US in community acquired AKI until we have any new studies......as the mortality in the above study was 24% for those with obstruction.

Sunday, November 21, 2010

Long known Vitamin D ..and physiology

Of all the vitamins..Vitamin D has recently featured in almost all medical journals..given the huge prevalance(57% of hospitalised pts in US) of Vitamin D deficiency and the association of it to many important disease processes known to man! 
Vitamin D has properties of both being a hormone..and a vitamin. Lets get a quick recap of the physiology.

There are 2 main forms of vitamin D: vitamin D3 (cholecalciferol) and vitamin D2 (ergocalciferol). Vitamin D3 is formed in the skin, after exposure to ultraviolet B radiation, from 7-dehydrocholesterol that resides in cell membranes.Vitamin D2 is obtained through irradiation of ergosterol in plants from sunlight, and enters our circulation through diet. Vitamin D3 also is available from animal sources, such as cod liver oil, salmon, mackerel, and herring. 
After vitamin D is ingested from the diet or synthesized in the skin, it is metabolized in the liver to a biologically
inactive 25-hydroxyvitamin D, 25(OH)D, which is the major circulating form of vitamin D. It is this form( 25-hydroxyvitamin D) of vitamin D that is used to determine a person’s vitamin D status. 25(OH)D is then converted into its active form 1,25 (OH)D by the kidneys. This then interacts with vitamin D receptors in the intestine and bone to augment intestinal calcium absorption and mobilize osteoclast activity. Non-calcium regulating tissues, such as the prostate,colon, and breast, locally convert 25(OH)D to 1,25(OH)2D....and this forms the basis of Vitamin D being involved in prevention of malignancy in these tissues,aas it facilitates programmed cell growth.

Although controversies exist regarding the cut off for calling deficiency( due to summer Vs winter, morning Vs evening etc)......widely accepted value of < 20ng/ml of 25(OH)D is considered deficient ....21 - 29 is considered Vit D insufficiency......and > 30 ng/ml signifies sufficiency.  Without vitamin D, only 10% to 15% of dietary calcium and approximately 60% of phosphorus will be absorbed. The efficiency of calcium absorption is increased by 30% to 40%, and phosphorus by 80%, with the interaction of 1,25(OH)2D to its receptor.
I frequently got confused with the different names vit D has! 25(OH)D is an inactive form..but this is what we measure to diagnose deficiency. 1,25(OH)D is the active form..and we dont measure it. D2 & D3 are just numbers to describe the source of VitD....D2 (cholecalciferol) from human skin, and D3(ergocalciferol) from food products. 

Tuesday, October 26, 2010

Is hyperbilirubinemia protective ?

Well..a mild increase in unconjugated bilirubin may be a good thing to have!. Iam talking about patients with Gilbert's syndrome(GS) and patients with a mild elevation in their indirect bilirubin in the absence of liver disease. GS is a benign syndrome cause by reduced activity of enzyme UDP Glucronyl Transferase. In one of the famous prospective cohort studies- The British Regional Heat Study(BRHS) there was a U shaped relationship between bilirubin level and heart disease. Men with low bilirubin levels were found to have low concentrations of HDL cholesterol, low FEV1, and low serum albumin. This led to a small study in Univ of Utah...which showed a similar inverse relationship between bilirubin & heart disease.Another prospective study from Europe called PRIME study involving 10,000 men also showed that a slightly elevated bilirubin is a marker of protection against Coronary Heart Disease. Another strong pointer towards this trend is the lesser incidence of heart disease in patients with Gilbert's syndrome compared to general population (Atherosclerosis 2002)


This benefit has been explained on the basis of the antioxidant property of Bilirubin. It might prevent oxygen radicals from damaging the endothelium, and it also prevents oxidation of LDL particles. Bot these effects can explain a lower incidence of Ischemic heart disease in this population. Well....if this idea is true....then it should protect against stoke as well. 


Stroke & bilirubin - A 30% risk reduction in incidence of carotid plaques was found in patients with their bilirubin the highest quartile compared to bilirubin in lowest quartile (Stoke 2001).  recent study published in Stroke 2009 ...studying nearly 80,000 healthy patients showed a 20% risk reduction in ISCHEMIC stroke in patients with high bilirubin levels.
Aaand...it doesnt stop here! Another study from Annals of Hepatology published in 2008 showed that a 0.1 mg/dL increase in bilirubin level was associated with a 6% reduction in the odds of peripheral vascular disease (PAD). The benefit was noticed more in men than women. Another article in JAMA 2007 comparing diabetic pts with Gilbert's syndrome to normal people...showed a a significantly lower prevalence of hypertension, HbA1c, LDLl, total cholesterol, and triglyceride,CRP and higher levels of HDL. They also had a lower incidence of proteinuria as well (have a look at the table). Very recently ,an article in Kidney International (Oct 2010) shows that in rats who had hereditary hyperbilirubnemia had lower incidence of diabetic nephropathy.


It may be difficult to prove whether high bilirubin is an effect of body's need for an antioxidant...or it does genuinely protect against atherosclerosis. But bilirubin seems to offer a definite protection, and could be used as a reasonably good marker of vascular events. The main hindrance to bilirubin's use is that we cannot modify its level...to attain any of these benefits. A level just around upper limit of normal( upto 2.5 x normal in GS) would be the level talked about in the studies.

Tuesday, October 19, 2010

Beer potomania......

 Recently we had a gentle man who presented to us with seizures nearly 10 hours after drinking in a pub.His sodium was 115. He is someone who drinks 2-3 beers a day.Binges on weekends. Night before admission he had atleast 10 beers (as per friends). He had a low serum osmolality, and a urine osmolalty of 152 mosm/L. His Na was initially corrected with 3% NS upto 120, and then by water restriction. This guy had beer protomania.

The mechanism - Beer has a lot of water with  very low sodium and protein.Someone on a beer diet will roughly get 200 msosm/day(1L of beer has roughly 30 gm of Sodium) compared to an american diet which has 750mosm/day. Still the serum osmolaltiy is maintained.This is because ....with ingestion of so much water(in the form of beer), ADH secretion is at its lowest, and so the kidneys excrete a dilute urine.The kidneys can dilute the urine to a maximum of 50mosm/L. So for a guy who drinks 4L of beer and roughly takes 200 osmoles a day, can excrete the osmotic load in 4L of urine (50 mosm/L x 4 = 200 mosm). If he drinks a 5th litre of beer, then he would develop hyponatremia.

The Urine flow depends on the the number of osmoles excreted. So to call it beer potomania...you should have some one who has binged on a lot of beer(water) without eating anything(especially with salt). A low serum osmolality/ low urine osmolality with the above history will clinch this diagnosis. In many of these alcoholics..the situation may be complicated by the need for  5% dextrose following Vit B1 to prevent Wernicke's encephalopathy. Close monitoring and replacement is needed in those situations.

Thursday, September 30, 2010

Chlorthalidone.......what a miss!

Chlorthalidone is a diuretic acting on the distal convoluted tubule...same as Hydrochlorthiazide. It is a 'thiazide like diuretic'....as it has a different structure than thiazide diuretics, but acts on the same Na-Cl symporter in the DCT. Chlorthalidone first came to light ..when used in the MRFIT trial in the 1970s. Since then chlorthalidone has been the diuretic of choice in the major hypertension trials - ALLHAT, Hypertension Detection and Follow-up Program (HDFP), Systolic Hypertension in the Elderly Program (SHEP). And chlorthalidone was the only antihypertensive showing some mortality benefit in the ALLHAT trial. 
Inspite of these data, im surprised that we still chose HCTZ on top of chlorthalidone. I cant figure out a valid reason for this swap.(If anyone knows ...let me know)

Studies done to compare Chlorthalidone with HCTZ in the past(1976)..were very small..but they all showed that  chlorthalidone once a day is equally efficacious to HCTZ twice a day....in fact with a trend towards even better blood pressure control and a slightly lesser incidence of hypokalemia. A recent study from Iowa showed a superior antihypertensive effect of chlorthalidone than HCTZ. (again ...small study- 30 pts....short duration-8wks.....no hard outcomes.....but hard to discard!)


So......Chlorthalidone seems to have a definite edge over HCTZ both in reducing BP and in preventing adverse cardiac events..with a similar or may be a better side effect profile.
Why is this difference between the two ? Well...we know the answer to some extent. 
1. Chlorthalidone has a longer elimination half life (50 hrs Vs 10 hrs for HCTZ) -- this means more sustained antihypertensive effects. This has been nicely shown in the above study from Iowa.
2. Bioavailability is the same as HCTZ, but it is 99% protein bound..which helps limit glomerular filtration and excellent delivery to action sites thru secretion. HCTZ is 40% protein bound.
3. Chlorthalidone is 99% bound to RBC carbonic anhydrase ...which forms a reservoir for continued action. 
4.Chlorthalidone is a stronger inhibitor of Carbonic anhydrase than HCTZ.....adding to its diuretic effect.
5. Recently..it has been found that Chlorthalidone decreases platelet aggregation and promotes angiogenesis. 
(Hypertension .July 2010)
6. Finally ..COST . 30 tabs of 50mg Chlorthalidone - $20.00 (12.5 mg starting dose....once a day)
                              100 tabs of 50 mg HCTZ          - $ 16.00 (12.5 starting dose......twice a day)


So..if some one is on HCTZ and doing well...it will be reasonable to leave it. Other wise Im changing to Chlorthalidone. And this is easily the first choice thiazide for me!!
Anyone has an argument?!

Thursday, September 23, 2010

Hyperkalemia with beta blockers!

I recently had a Chronic kidney diesease patient on low dose Ramipril with a stable potassium level for many months, got admitted to the hospital for an hypertensive urgency.Her renal function & K were stable on admission. She was started on a Labetalol infusion overnight.Next day her potassium level was 6.9mEq/L, and she needed two Insulin dextrose treatment( couple of hours apart) to get that back to normal. Her TTKG(transtubular potassium gradient) was 4. This is hyperkalemia due to Labetalol.

Lets see how........ There are 2 mechanisms by which betablockers can cause hyperkalemia.
1. Beta blockers suppress catecholamine-stimulated renin release, thereby decreasing aldosterone synthesis.
2. More importantly nonselective beta blockers decrease cellular uptake of potassium.(NEJM )
                          
The primary mechanism for handling an acute potassium load is by redistribution into the cells.Normally, agonist binding to the beta2-adrenergic receptor stimulates the formation of cyclic AMP, which acts through protein kinase A to phosphorylate and activate the Na-K-ATPase pump, leading to the influx of potassium into cells. Competitive inhibition of the beta2 receptor by beta blockers decreases Na-K-ATPase function and reduces potassium uptake by cells.
So..this seems to happen only with non-selective beta blockers(Labetalol, Propranolol, Carvedilol, Nadolol).
Based on some retrospective studies, nonselective beta blockers have caused or contributed to hyperkalemia in 4% to 17% of hospitalized patients studied.
Have a look at this study on renal transplant patients receiving Labetalol, ended up having hyperkalemia more frequently than patients treated with agents other than labetalol.(AJNephrology 2002). The fact that hyperkalemia developed immediately after Labetalol infusion strengthens the hypothesis of blocking cellular intake of potassium than catecholamine suppression as the primary cause of Hyperkalemia with non selective betablockers.

So...just add nonselective betablockers to your differential for Hyperkalemia ......especially in patients who cannot excrete potassium properly (renal failure, on ace-i or ARD, spironolactone etc)
Sorry guys...I could not get full text of articles...will update once I get access to them!

Thursday, September 2, 2010

Midodrine may not be there!

The latest medication which has come under FDA's radar in the last month...is the drug that has been increasingly used by nephrologists and heaptologists--- MIDODRINE .
On Aug 17th 2010 FDA issued a proposal to withdraw midodrine from the market within 30 days. 
So I decided to look into the evidence behind using Midodrine. 
Let me start with a little background on Midodrine---- It is a alpha agonist, and acts on venous and arteriolar vasculature producing increased vascular tone. It increases sitting, standing and lying BP.So the most common side effect reported is supine hypertension.


It is surprising that there is very scarce data on the clinical effectiveness of Midodrine. So far 3 randomised trials have been done. One is 3 weeks duration, and the other two are of 1-2 days duration!!! All studies were done on patients with orthostatic hypotension .
In the 3 week trial(JAMA 1997), pts on Midodrine(10 mg tid) had significantly higher (by about 20 mmHg) 1-minute standing systolic pressure 1 hour after dosing (blood pressures were not measured at other times) for all 3 weeks.They also had a similar increase in supine and sitting BP. And 25% of the 82 pts on Midodrine  dropped out of the study(due to pilomotor reactions, supine HTN, urinary retention)
The 1 & 2 day study also showed similar improvements in standing BP.In 1 day study the supine BP was >200 systolic in 22% pts on 10mg and 45% pts on 20mg. This elevated BP lasted for 6 hours after the dose. 


The only indication midodrine is approved is for Orthostatic hypotension. This has been extrapolated, and has been commonly used in one other setting...which is for treating hypotension during dialysis. There are nearly 10 studies on this..but again..the largest of these studies had 21 participants, and with short follow up. Have a look at this review from 2004. 


So there seems to be no real convincing data to support Midodrine. The Shire pharmaceuticals agreed to perform post marketing trials..but failed to do any. And thats the reason for FDA's proposal. It seems unlikely that Midodrine will be available in the near future(as early as this month).So what this means is..that physicians and patients on Midodrine have to be prepared to find an alternated  drug pretty soon!

Tuesday, August 31, 2010

Is one kidney enough for me?

Well, Iam doing Transplant Nephrology right now. So I though I will chip in with this topic ....that many patients ask about. These are some of the facts that we know about donating a kidney......
Usually donors have be healthy..and ideally free of chronic problems especially Diabetes, cancer, strong family history of renal disease ending on dialysis, and without anatomical abnormalities like Polycystic kidneys.
So we are dealing with a group of healthy people. Consequences of donating may be divided into two...for the ease of explaining..

1. Issues with surgery - The surgery for removing is mostly done laparoscopically these days.(usually left kidney is removed due to ease of removal ). On a recent study in JAMA ,the mortality in the first 90 days is around 3/10,000 patients. Mostly due to bleeding, thromboembolic disease etc. After 1 year the mortality equals the mortality with a comparable healthy cohort.

2. Issues with loss of kidney mass -  Since 50% of the nephron mass is lost, its expected that their left over kidney swells up a little to compensate, and creatinine can theoretically double. But usually creatinine goes back to normal or settles within 40% above baseline. The other theoretical risks that need to be watched for over the next 2 years are 1.Hypertension ( not significantly high than in normal population)
                                       2. Protenuria (significance is not really known)
 As I mentioned above, the mortality is the same for these people as for someone who has 2 kidneys.

One advantage of donating a kidney is...if in case the donor ends on Dialysis either due to trauma, cancer or CKD), then they will be considered as high priority, and will get transplanted (if they dont have a living donor) within 6 months.

So..go ahead ..encourage patients to donate...if they can...!!!!

Friday, August 20, 2010

urinalysis in rhabdomyolysis

Urinalysis is an important part of the evaluation of any renal disorder.It is very simple, easy to perform and gives quick and valuable information. Out of the whole array of information, lets concentrate on the test that need to be done and are useful for diagnosing and managing rhabdomyolysis

Urine volume - ask about this in the history as it may give an idea about the renal involvement while you wait for the Creatinine. Of course it is helpful in monitoring response to fluids and recovery of function.

Color of urine - the myoglobin released from the muscles, turns the urine brown or red due to the heme content.

Ph of urine - Its useful to check Ph as myoglobin has shown to precipitate when Ph drops below 5.5. So check this initially and start with aggressive fluid resuscitation. recheck the Ph after 2-4 L boluses ,and if its still less than 7 , infusing bicarbonate will help increase the urine Ph and prevent precipitation of myoglobin in the tubules.


Blood & RBC count - it is well known to everyone that the urine is positive for blood and negative for RBCs( or has less than 5 cells/hpf) . The dipstix we use is sensitive for picking heme protein and myoglobin breaks down into heme, so is the positive finding of blood ,with no RBC s under the microscope. So in this scenario we assume its due to myoglobin.

Casts - finding of casts are useful diagnostically, as they are in any other case of AKI. In case of rhabdomyolysis, the casts are formed as a result of reaction between Tamm Horsfall protein and myoglobin.The casts are usually pigmented.

Urine electrolytes - In rhabdomyolysis you can calculate the Fractionl excretion of Sodium, and this will give an idea about the likely mechanism of AKI. Both pre renal and ATN can contribute to AKI in rhabdomyolysis.
Hope you all have fun with spinning the urine next time!

Wednesday, August 4, 2010

hypokalemia and hepatic encephalopathy - good or bad??


Hypokalemia can be a precipitating factor for hepatic encephalopathy, and its not uncommon, as we use large doses of loop diuretics in these patients.

Although, the mechanism is not entirely clear, the likely hypothesis is as follows:
*Hypokalemia causes the movement of potassium out of the cells in proximal tubule.
*To maintain electric neutrality, H+ ions move into the cells leading to intracellular acidosis
*This triggers the conversion of glutamine in the proximal tubule, to NH4+ and bicarbonate. *Ammonia (NH3+ and NH4+) is selectively, either excreted in the urine or returned to the renal venous circulation (~25-45%).
*Ammonia, that subsequently enters portal circulation, is not metabolized by the cirrhotic liver, therefore likely to precipitate encephalopathy.

Frequently, hyperkalemia, and not hypokalemia, is a cause of concern among physicians, and frequently leads to discontinuation of spironolactone, administration of loop diuretics, dietary potassium restrictions, all of which further add to the risk of encephalopathy. So, conversely, can high potassium be protective?

Potassium competes with NH4+ for absorption by the NKCC2 transporter at the thick ascending limb of loop of henle, thereby reducing ammonia accumulation in the medullary interstitium and hence less ammonia available for absorption in the systemic circulation. In an interesting study done by Zavagli et al, patients with higher potassium levels (5.4-5.5 meq/l) had a much better survival and less hepatic encephalopathy episodes as compared to patients with lower potassium levels (3.4-3.5meq/l).

Given these, it would be reasonable to try and keep these patients at a high normal range of potassium. As we all know potassium is a double edged sword.So this has to be monitored closely so they dont become severely hyperkalemic (> 5.5meq/L) .